QQ客服 官方微博 反馈留言

	Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism
	Yang, Sheng-Hua; Xu, Rui-Xia; Cui, Chuan-Jue; Wang, Yin; Du, Ying; Chen, Zhi-Guo; Yao, Yu-Hong; Ma, Chun-Yan; Zhu, Cheng-Gang; Guo, Yuan-Lin
	2018
卷号	17期号:1页码:48
关键词	PCSK9 Low-density lipoprotein receptor Glucagon-like peptide-1 Liraglutide Type 2 diabetes mellitus
ISSN号	1475-2840
DOI	10.1186/s12933-018-0689-9
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6360243
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Yang, Sheng-Hua,Xu, Rui-Xia,Cui, Chuan-Jue,et al. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism[J],2018,17(1):48.
APA	Yang, Sheng-Hua.,Xu, Rui-Xia.,Cui, Chuan-Jue.,Wang, Yin.,Du, Ying.,...&Li, Jian-Jun.(2018).Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.,17(1),48.
MLA	Yang, Sheng-Hua,et al."Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism".17.1(2018):48.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。